ÂÜÀòÂÒÂ×

Debra Peattie is the current Commercialization Advisor at GRO Biosciences. Debra has over 25 years of experience in the pharmaceutical and biotechnology industries, with a focus on business development and strategy.

Peattie began their career as a Chief Scientific Officer at Valeo Medical, where they were responsible for identifying and developing new products and technologies. Debra then transitioned to the role of Managing Partner at SV Bio Ventures, a venture capital firm focused on life sciences investments. In this role, they were responsible for evaluating and investing in early-stage companies.

In 2009, Peattie joined Cubist Pharmaceuticals as Director of Strategy & Planning. In this role, they were responsible for identifying growth opportunities for the company and developing strategies to expand the product pipeline and customer base.

In 2011, Peattie left Cubist to join Harvard University as Director of Business Development for the Office of Technology Development. In this role, they were responsible for evaluating the translation potential of research discoveries and commercializing life sciences discoveries via corporate alliances and out-licensing agreements.

In 2013, Peattie joined GlaxoSmithKline as Senior Director of Future Pipelines for Discovery Partnerships with Academia. In this role, they sourced and transacted academic research with novel therapeutic potential and devised and executed strategies to develop emerging drug discovery technologies.

Peattie has been with GRO Biosciences since 2019, where they serve as Commercialization Advisor.

Debra Peattie received their PhD in Biochemistry and Molecular Biology from Harvard University. Debra then went on to receive their Master of Business Administration from Harvard Business School. After that, they were a Helen Hay Whitney Post-doctoral Fellow in Biochemistry at Stanford University. Finally, they received their BA in Chemistry from Hollins University.